Finally, we demonstrate that the investigated MIR149, MIR605, MIR938, DROSHA, MIR200C, MIR499A, MIRLET7A1, MIR323B, and MIR2053 could potentially modulate the therapeutic response of standard treatment for ALL. Here, MIR499A is linked to acute lymphoblastic leukemia.